PureTech Health (OTCMKTS:PTCHF – Get Free Report) will likely be releasing its resultson Tuesday, September 22nd. Analysts expect PureTech Health to post earnings of ($0.1160) per share and revenue of $24.80 million for the quarter.
PureTech Health Price Performance
PTCHF opened at $1.65 on Monday. PureTech Health has a 1 year low of $1.53 and a 1 year high of $1.92. The firm has a 50 day moving average price of $1.58 and a 200 day moving average price of $1.65.
About PureTech Health
PureTech Health PLC (“PureTech”) is a clinical-stage biopharmaceutical company focused on the development of innovative medicines to address serious diseases with high unmet medical need. Founded in 2005 by Daphne Zohar and headquartered in Boston, Massachusetts with operations in both North America and Europe, PureTech applies its proprietary platforms to advance therapeutic candidates across immunology, neuroscience and lymphatic-focused indications.
The company leverages three core technology platforms—immune tolerance, gut-targeted delivery and lymphatic transport—to develop novel molecules designed for enhanced specificity and durability of effect.
Further Reading
- Five stocks we like better than PureTech Health
- NVIDIA Just Named AI’s Next Bottleneck—And These 3 Stocks Sit Right In It
- Gold Has Gone Sideways, But These 3 Stocks Haven’t
- The AI Bottleneck Is Not Chips Anymore and 3 Pipeline Stocks Are Cashing In
- These 3 Stocks Under $20 Have Wall Street Looking Past the Share Price
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
